Safety, tolerability and pharmacokinetics of oral S-3304, a novel matrix metalloproteinase inhibitor, in single and multiple dose escalation studies in healthy volunteers

International Journal of Clinical Pharmacology and Therapeutics

Volumn 43, Issue 6, 2005, Pages 282-293

  van Marle, S ^a   van Vliet, A ^a   Sollie, F ^a   Kambayashi, Yoshikazu ^b   Yamada Sawada, T ^b  

^a PRA International USA   (Netherlands)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Clinical study; First in man; MMP inhibitor; S 3304; Sulfonamide

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ALANINE AMINOTRANSFERASE; HYDROCORTISONE; MATRIX METALLOPROTEINASE INHIBITOR; PLACEBO; S 3304; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPHONIA; EDEMA; EPISTAXIS; EYE PAIN; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GLOSSITIS; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPESTHESIA; INCREASED APPETITE; LIVER DYSFUNCTION; MALE; MOTOR DYSFUNCTION; MULTIPLE DRUG DOSE; MYALGIA; NAUSEA; NORMAL HUMAN; OTALGIA; PARESTHESIA; PHARYNGITIS; PHLEBITIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RIGOR; SENSORY DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; THORAX PAIN; URINARY EXCRETION; VOMITING;

EID: 21044433055     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp43282     Document Type: Article

References (19)

1. Baxter AD, Bird JB, Bannister R, Bhogal R, Manallack DT, Watson RW, Owen DA, Montana J, Henshilwood J, Jackson RC 2000 D1927 and D2163: novel mercaptoamide inhibitors of matrix metalloproteinases. In: Clendeninn NJ, Appelt K (eds) Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Humana Press, Totowa, New Jersey, 193-221
2. Bramhall SR, Hallissey MT, Whiting J, Scholefield J, Tierney G, Stuart RC, Hawkins RE, McCulloch P, Maughan T, Brown PD, Baillet M, Fielding JW 2002 Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 86: 1864-1870
3. Da Ros L, Squassante L, Milleri S 2003 Dose linearity of lacidipine pharmacokinetics after single and repeated oral doses in healthy volunteers. Clin Pharmacokinet 42: 99-106
4. Folkman J 1995 Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds) The Molecular Basis of Cancer. Saunders, Philadelphia, 206-232
5. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P 1989 The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450 IIIA induction. Br J Clin Pharmacol 28: 373-387
6. Grochow L, O'Reilly S, Humphrey R, Sundaresan P, Donehower R, Sartorius S, Kennedy MJ, Armstrong D, Carducci M, Sorensen JM, Kumor K 1998 Phase I and pharmacokinetic study of the matrix metalloproteinase inhibitor (MMPI), BAY12-9566 [Abstract 822]. 34th American Society of Clinical Oncology, May 16 - 19, Los Angeles
7. Ikeda M, Maekawa R, Tanaka H, Matsumoto M, Takeda Y, Tamura Y, Nemori R, Yoshioka T 2000 Inhibition of gelatinolytic activity in tumor tissues by synthetic matrix metalloproteinase inhibitor: application of film in situ zymography. Clin Cancer Res 6: 3290-3296
8. Kato I, Yoshida T, Muranaka R, Kondo K, Miyake Y, Hirose H, Sameshima H, Izumi H 2002 Non-clinical assessments of safety profiles of S-3304, a novel matrix metalloproteinase inhibitor. Eur J Cancer 38: S76
9. King J, Zhao J, Clingan P, Morris D 2003 Randomised double blind placebo control study of adjuvant treatment with the metalloproteinase inhibitor, marimastat, in patients with inoperable colorectal hepatic metastases: Significant survival advantages in patients with musculoskeletal side effects. Anticancer Res 23: 639-645
10. Lima JJ, MacKichan JJ, Libertin N, Sabino J 1993 Influence of volume shifts on drug binding during equilibrium dialysis: correction and attenuation. J Pharmacokinet Biopharm 11: 483-498
11. MacDougall JR, Matrisian LM 1995 Contribution of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 141: 351-362
12. Maekawa R, Ikeda M, Yoshioka T, Sugita K 2002 Non-clinical therapeutic studies of S-3304, a novel matrix metalloproteinase inhibitor. Eur J Cancer 38: S80
13. Matrisian LM 1993 Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6: 121-125
14. Pithavala Y, Shalinsky D, Wilding G, Hande K, Dixon M, Collier M 1999 Comparison of Preclinical Efficacy and Associated Plasma Concentrations of AG3340, a Matrix Metalloproteinase (MMP) Inhibitor, with Plasma Concentrations Achieved Clinically [Abstract 860]. 35th American Society of Clinical Oncology, May 15 - 18, Atlanta
15. Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T, Kaldjian E, Welgus H, Baragi V 2003 Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 48: 1742-1749
16. Shalinsky DR, Shetty B, Pithavala Y, Bender S, Neri A, Webber S, Appelt K, Collier M 2000 Prinomastat. A potent and selective matrix metalloproteinase inhibitor - preclinical and clinical development for oncology. In: Clendeninn NJ, Appelt K (eds) Cancer Drug Discovery and Development: Matrix Metalloproteinase Inhibitors in Cancer Therapy. Humana Press, Totowa, New Jersey, 143-173
17. Takeuchi M, Nezasa K, Kawahara S, Inazawa K, Baba T, Sakamoto K, Koike M, Yoshikawa T 2002 Non-clinical assessments of drug metabolism and pharmacokinetics of S-3304, a matrix metalloproteinase inhibitor. Eur J Cancer 38: S72
18. Tamura Y, Watanabe F, Nakatani T, Yasui K, Fuji M, Komurasaki T, Tsuzuki H, Maekawa R, Yoshioka T, Kawada K, Sugita K, Ohtani M 1998 Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives. J Med Chem 41: 640-649
19. Yoshioka T, Watanabe F, Tsuzuki H, Misaki S, Takasu N, Kawada K, Ohtani M 2002 In vitro pharmacological profiles and in vivo anti-angiogenesis activity of S-3304, a novel matrix metalloproteinase inhibitor. Eur J Cancer 38: S81